There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ultragenyx Pharmaceutical, Inc. (RARE) and ACADIA Pharmaceuticals Inc (ACAD) with bullish sentiments.
Ultragenyx Pharmaceutical, Inc. (RARE)
Cowen & Co. analyst Yaron Werber maintained a Buy rating on Ultragenyx Pharmaceutical, Inc. today and set a price target of $79. The company’s shares closed yesterday at $60.26.
According to TipRanks.com, Werber is a 5-star analyst with an average return of 12.3% and a 64.0% success rate. Werber covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Prevail Therapeutics Inc, and Stoke Therapeutics Inc.
Currently, the analyst consensus on Ultragenyx Pharmaceutical, Inc. is a Strong Buy with an average price target of $79.67.
See today’s analyst top recommended stocks >>
ACADIA Pharmaceuticals Inc (ACAD)
Cowen & Co. analyst Ritu Baral maintained a Buy rating on ACADIA Pharmaceuticals Inc today and set a price target of $42. The company’s shares closed yesterday at $24.58.
According to TipRanks.com, Baral is a top 100 analyst with an average return of 24.4% and a 50.1% success rate. Baral covers the Healthcare sector, focusing on stocks such as Milestone Pharmaceuticals Inc, Allena Pharmaceuticals Inc, and NGM Biopharmaceuticals Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for ACADIA Pharmaceuticals Inc with a $40.20 average price target, a 63.5% upside from current levels. In a report issued on July 22, J.P. Morgan also maintained a Buy rating on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
